- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 8, 2024
Compared with alteplase, TNK was effective at doses of 0.1 mg/kg and 0.25 mg/kg without increased risk of symptomatic intracerebral hemorrhage (sICH), but patients treated with TNK 0.4 mg/kg showed increased odds of sICH. In conclusion, compared with alteplase, intravenous thrombolysis with TNK at dose of 0.25 mg/kg has a better efficacy and similar safety profile and is a reasonable option for patients with AIS.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Journal: Moving From Alteplase to Tenecteplase for Acute Ischemic Stroke-Mayo Clinic Experience. (Pubmed Central) - Jan 8, 2024
In conclusion, compared with alteplase, intravenous thrombolysis with TNK at dose of 0.25 mg/kg has a better efficacy and similar safety profile and is a reasonable option for patients with AIS. Tenecteplase use as the thrombolytic agent in acute ischemic stroke was associated with lower rates of symptomatic intracranial hemorrhage, higher rates of spontaneous recanalization, but similar door-to-needle time and 90-day modified Rankin Scale as compared with tissue plasminogen activator.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Comparative safety of tenecteplase vs alteplase for acute ischemic stroke. (Pubmed Central) - Jan 2, 2024
In the context of a stroke telemedicine program, the rates of hemorrhage observed with either agent were lower than expected based on prior trials and registry data. The more easily prepared tenecteplase was associated with a lower door-to-needle time.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tying It ALTogether: Real-World Application (Congress Digital) - Dec 24, 2023 - Abstract #SCCM2024SCCM_664;
No abstract available When presented with cases regarding patients presenting with stroke, discuss who would be a good candidate for tenecteplase and considerations when using tenecteplase vs alteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Logistics Logistics (Congress Digital) - Dec 24, 2023 - Abstract #SCCM2024SCCM_635;
This change requires numerous considerations including getting buy in from providers, making the formulary change, and educating nurses and providers on administration and dosing. This session will focus on the logistical issues to consider when making the transition from Alteplase to Tenecteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Challenging the Status Quo: Scientific Rationale for Tenecteplase Versus Alteplase Therapy (Congress Digital) - Dec 24, 2023 - Abstract #SCCM2024SCCM_602;
Tenecteplase has emerged as an alternative to alteplase for thrombolytic therapy in patients with acute ischemic stroke with evidence suggesting potential improved outcomes in select patient populations. Scientific evidence, operational logistics, and cost considerations can guide institutional conversations when determining preferred formulary thrombolytic therapy.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ALT With the Old and TEN With the New: Converting from Alteplase to Tenecteplase (Congress Digital) - Dec 24, 2023 - Abstract #SCCM2024SCCM_569;
Speakers will engage audience members to solicit thoughts and allow for questions. Learning Objectives: Review the literature surrounding the use of tenecteplase versus alteplase and considerations before switching agents at an institution Identify key multiprofessional members essential to facilitating and assisting with a transition from alteplase to tenecteplase Discuss considerations and strategies to ensure a smooth transition in prescribing, ordering, administration, and monitoring of the medication
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Clinical, Journal: Intra-arterial tenecteplase following endovascular therapy in patients with acute posterior circulation arterial occlusion: study protocol and rationale. (Pubmed Central) - Dec 21, 2023
P2/3
Learning Objectives: Review the literature surrounding the use of tenecteplase versus alteplase and considerations before switching agents at an institution Identify key multiprofessional members essential to facilitating and assisting with a transition from alteplase to tenecteplase Discuss considerations and strategies to ensure a smooth transition in prescribing, ordering, administration, and monitoring of the medication ATTENTION-IA will provide definitive evidence for the efficacy and safety of adjunct intra-arterial tenecteplase after successful EVT in patients with an acute posterior circulation arterial occlusion stroke presenting within 24 hours of symptom onset.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion, Trial completion date, Trial primary completion date: ALLY: Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy Pilot Trial (clinicaltrials.gov) - Dec 6, 2023
P2, N=20, Completed,
ATTENTION-IA will provide definitive evidence for the efficacy and safety of adjunct intra-arterial tenecteplase after successful EVT in patients with an acute posterior circulation arterial occlusion stroke presenting within 24 hours of symptom onset. Recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Sep 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal, Real-world evidence, Real-world: Tenecteplase real-world data: A three phase sequential comparison. (Pubmed Central) - Nov 27, 2023
There was no inter-group difference when comparing the two alteplase phases. Our results suggest that previously reported benefits from tenecteplase in a real-world setting were not likely attributable to a temporal confounding.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Nov 8, 2023
P3, N=1490, Completed,
Thrombolysis with alteplase or tenecteplase did not cause ICH in any mimics under 60 years. Active, not recruiting --> Completed
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial completion date, Trial primary completion date: DIVAr (clinicaltrials.gov) - Nov 7, 2023
P=N/A, N=294, Completed,
Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2023 --> Sep 2023 Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2023 --> Sep 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Acute management of childhood stroke. (Pubmed Central) - Nov 3, 2023
Recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2023 --> Sep 2023 There have been significant advances in the hyperacute care of children with ischemic stroke and early diagnosis and targeted management are of the upmost importance in improving long-term outcomes.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Journal: Tenecteplase, 0.4?mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR-TEST and NOR-TEST 2A. (Pubmed Central) - Nov 3, 2023
P3
A lower tenecteplase dose should be tested in future trials. Registration URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01949948, NCT03854500.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion date, Trial primary completion date: RESTORE-MI: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. (clinicaltrials.gov) - Oct 30, 2023
P3, N=445, Recruiting,
The effect of time to tenecteplase administration on clinical outcomes is like that of alteplase, with faster administration resulting in better clinical outcomes. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: The Application of Data Envelopment Analysis to Emergency Departments and Management of Emergency Conditions: A Narrative Review. (Pubmed Central) - Sep 28, 2023
We thoroughly assess the methodological basis of the papers, offering detailed explanations regarding the applied models, selected inputs and outputs, and all relevant methodologies. In conclusion, we explore several ways to enhance DEA's status, transforming it from a mere technical application into a strong methodology that can be utilized by healthcare managers and decision-makers.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Efficacy and safety of tenecteplase in comparison to alteplase in acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 15, 2023
In conclusion, we explore several ways to enhance DEA's status, transforming it from a mere technical application into a strong methodology that can be utilized by healthcare managers and decision-makers. Based on our meta-analysis, tenecteplase has similar efficacy and safety to alteplase, with a more promising effect in patients with LVO.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial termination: NOR-TEST 2: The Norwegian Tenecteplase Stroke Trial 2 (clinicaltrials.gov) - Sep 15, 2023
P3, N=201, Terminated,
Based on our meta-analysis, tenecteplase has similar efficacy and safety to alteplase, with a more promising effect in patients with LVO. Recruiting --> Terminated; Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Medical Management of Acute Cerebral Ischemia. (Pubmed Central) - Sep 13, 2023
Expansion of the thrombolysis eligibility criteria are discussed. Tenecteplase as a promising new thrombolytic is explored and the evidence supporting the use of Mobile Stroke Units is presented.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke. (Pubmed Central) - Sep 2, 2023
Tenecteplase treatment was cost-effective for all AIS patients (including AIS patients with LVO) compared to alteplase. The finding supports the broader use of tenecteplase in acute stroke care, as health outcomes improve at acceptable costs while having practical advantages, and a similar safety profile.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase. (Pubmed Central) - Aug 25, 2023
Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase. (Pubmed Central) - Aug 14, 2023
Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Adverse events, Real-world evidence, Real-world: Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS). (Pubmed Central) - Aug 9, 2023
Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of AIS patients undergoing thrombolytic therapy.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 8, 2023
This meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
|
